Efficacy and Safety of Bimekizumab in Patients with Moderate-to-Severe Hidradenitis Suppurativa (BE HEARD I and II)

The presentation focuses on the efficacy and safety of bimekizumab for treating moderate-to-severe hidradenitis suppurativa, highlighting recent clinical studies. It underscores the persistent medical need for better therapies, as current FDA-approved options are limited to adalimumab and circumscribed to specific conditions. Bimekizumab acts on IL-17A and IL-17F cytokines, crucial in both acute and chronic disease phases, demonstrating significant improvements in patient outcomes over 48 weeks. The speaker discusses clinical trial results, contrasting patient improvements with placebo and examining how the timing of treatment impacts efficacy. Limitations of these studies are noted, including short placebo duration and challenges in assessing effects amidst rescue medications. An evolving pathogenesis model for hidradenitis is presented, emphasizing the need to target therapeutic molecules effectively. A shift towards spatial proteomics and transcriptomics is recommended, with emerging applications noted in identifying novel treatment pathways. The latter part discusses suboptimal atopic dermatitis guidelines that highlight a disconnect in dermatological ownership of diseases and therapeutic recommendations, stressing the need for prompt updates and unified approaches in creating relevant clinical guidelines. The presentation ultimately advocates for the integration of emerging scientific techniques with clinical practice to enhance patient outcomes.